Literature DB >> 27165275

[Treatment of posterior noninfectious uveitis : Current situation and future developments].

U Pleyer1, D Pohlmann2, N Stübiger2.   

Abstract

Treatment of autoimmune diseases has undergone significant changes and developments in recent years. New classes of active substances, in particular biologics and small molecules have resulted in previously unknown success in the treatment of many diseases. In particular patients suffering from autoimmune rheumatic or dermatological diseases have benefited. For autoimmune uveitis there are numerous reports indicating excellent therapeutic and preventive effects; however, statutory approval for therapy in adults is still pending. This article outlines recent advances and future therapeutic options for the treatment of posterior segment noninfectious uveitis.

Entities:  

Keywords:  Biologicals; Corticosteroids; Cytokines; Small molecular weight inhibitors; Uveitis

Mesh：

Substances：

Year:  2016        PMID： 27165275     DOI： 10.1007/s00347-016-0267-z

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  33 in total

1.  Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats.

Authors:  S Kurose; E Ikeda; M Tokiwa; N Hikita; M Mochizuki
Journal:  Exp Eye Res       Date:  2000-01       Impact factor: 3.467

Review 2.  Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel.

Authors:  D A Jabs; J T Rosenbaum; C S Foster; G N Holland; G J Jaffe; J S Louie; R B Nussenblatt; E R Stiehm; H Tessler; R N Van Gelder; S M Whitcup; D Yocum
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

3.  Behçet's syndrome: treatment with recombinant leukocyte alpha-interferon.

Authors:  D Tsambaos; D Eichelberg; M Goos
Journal:  Arch Dermatol Res       Date:  1986       Impact factor: 3.017

Review 4.  [Janus-faced?: Effects and side-effects of interferon therapy in ophthalmology].

Authors:  N Stübiger; S Winterhalter; U Pleyer; D Doycheva; M Zierhut; C Deuter
Journal:  Ophthalmologe       Date:  2011-03       Impact factor: 1.059

Review 5.  Understanding uveitis: the impact of research on visual outcomes.

Authors:  Marc D de Smet; Simon R J Taylor; Bahram Bodaghi; Elisabetta Miserocchi; Philip I Murray; Uwe Pleyer; Manfred Zierhut; Talin Barisani-Asenbauer; Phuc LeHoang; Sue Lightman
Journal:  Prog Retin Eye Res       Date:  2011-07-22       Impact factor: 21.198

6.  Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.

Authors:  Ahmet Gül; Ilknur Tugal-Tutkun; Charles A Dinarello; Leonid Reznikov; Bahar Artim Esen; Amer Mirza; Patrick Scannon; Alan Solinger
Journal:  Ann Rheum Dis       Date:  2011-11-14       Impact factor: 19.103

Review 7.  Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis.

Authors:  Dicle Hazirolan; Uwe Pleyer
Journal:  Ophthalmic Res       Date:  2012-12-15       Impact factor: 2.892

8.  Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.

Authors:  John H Kempen; Ebenezer Daniel; Sapna Gangaputra; Kurt Dreger; Douglas A Jabs; R Oktay Kaçmaz; Siddharth S Pujari; Fahd Anzaar; C Stephen Foster; Kathy J Helzlsouer; Grace A Levy-Clarke; Robert B Nussenblatt; Teresa Liesegang; James T Rosenbaum; Eric B Suhler
Journal:  Ophthalmic Epidemiol       Date:  2008 Jan-Feb       Impact factor: 1.648

9.  Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis.

Authors:  Takeru Yoshimura; Koh-Hei Sonoda; Nobuyuki Ohguro; Yoshiyuki Ohsugi; Tatsuro Ishibashi; Daniel J Cua; Takashi Kobayashi; Hiroki Yoshida; Akihiko Yoshimura
Journal:  Rheumatology (Oxford)       Date:  2009-01-22       Impact factor: 7.580

Review 10.  Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.

Authors:  Giuseppe Lopalco; Luca Cantarini; Antonio Vitale; Florenzo Iannone; Maria Grazia Anelli; Laura Andreozzi; Giovanni Lapadula; Mauro Galeazzi; Donato Rigante
Journal:  Mediators Inflamm       Date:  2015-02-16       Impact factor: 4.711
View more
  2 in total

1.  [Optimization of therapy of autoimmune diseases of the eye : Novel approaches].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2016-05       Impact factor: 1.059

2.  [DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Authors: 
Journal:  Ophthalmologe       Date:  2017-12       Impact factor: 1.059
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.